Wealth & Investing
New York City, United States
Investments and Asset Management
‘It’s important to communicate that the biotechnology industry of today is not the same as it was 10 or 15 years ago,’ says Geoffrey Hsu, who manages the Biotech Growth Trust on behalf of OrbiMed.
‘Now we have mature companies with a billion dollars of revenue or more. They are not as risky as some of the smaller companies out there.’
Hsu studied for a degree in chemistry at Harvard before spending two years at Lehman Brothers. He returned to Harvard to study medicine, before switching to the MBA programme. He joined OrbiMed on graduation in 2002, was promoted to general partner in 2009 and now oversees the trust’s investments.
Top Recommended 2021, Life Sciences